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Abstract
Background: The protease inhibitor, TL-3, demonstrated broad efficacy in vitro against FIV, HIV
and SIV (simian immunodeficiency virus), and exhibited very strong protective effects on early
neurologic alterations in the CNS of FIV-PPR infected cats. In this study, we analyzed TL-3 efficacy
using a highly pathogenic FIV-C isolate, which causes a severe acute phase immunodeficiency
syndrome, with high early mortality rates.
Results: Twenty cats were infected with uncloned FIV-C and half were treated with TL-3 while
the other half were left untreated. Two uninfected cats were used as controls. The general health
and the immunological and virological status of the animals was monitored for eight weeks
following infection. All infected animals became viremic independent of TL-3 treatment and seven
of 20 FIV-C infected animals developed severe immunodepletive disease in conjunction with
significantly (p ≤ 0.05) higher viral RNA loads as compared to asymptomatic animals. A marked and
progressive increase in CD8+ T lymphocytes in animals surviving acute phase infection was noted,
which was not evident in symptomatic animals (p ≤ 0.05). Average viral loads were lower in TL-3
treated animals and of the 6 animals requiring euthanasia, four were from the untreated cohort. At
eight weeks post infection, half of the TL-3 treated animals and only one of six untreated animals
had viral loads below detection limits. Analysis of protease genes in TL-3 treated animals with
higher than average viral loads revealed sequence variations relative to wild type protease. In
particular, one mutant, D105G, imparted 5-fold resistance against TL-3 relative to wild type
protease.
Conclusions: The findings indicate that the protease inhibitor, TL-3, when administered orally as
a monotherapy, did not prevent viremia in cats infected with high dose FIV-C. However, the
modest lowering of viral loads with TL-3 treatment, the greater survival rate in symptomatic
animals of the treated cohort, and the lower average viral load in TL-3 treated animals at eight
weeks post infection is indicative of a therapeutic effect of the compound on virus infection.
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Background
Feline immunodeficiency virus (FIV) is a lentivirus that
infects domestic and feral cat populations worldwide.
Infected cats exhibit similar disease patterns as human
immunodeficiency virus (HIV) infected patients by devel-
oping multiple immuno-depletive symptoms collectively
referred to as acquired immunodeficiency syndrome
(AIDS). As with HIV, differences in virulence among the
different FIV subgroups are evident [1-4]. Thus, the cat
represents an amenable animal model for testing certain
anti-HIV-1 drug modalities in vivo.
One of the major breakthroughs in HIV-1 treatment has
been the use of specific inhibitors of the viral aspartic pro-
tease family as part of a drug cocktail, called highly active
anti-retroviral therapy (HAART), with the ultimate goal of
suppressing HIV-1 replication in patients to low or unde-
tectable levels [5-8]. Effective HAART therapy continues to
be dependent on the development of new drug modalities
due to the rapid mutation rate of HIV-1, leading to drug
resistance development [9]. Therefore, an effective small
animal model for evaluating new drugs and treatments for
HIV is of paramount importance. Experimental testing of
new protease inhibitors in cats has been of limited success
due to the ineffectiveness of HIV-1 specific protease inhib-
itors against FIV [10,11]. The promising development of
the protease inhibitor TL-3, which inhibits FIV, HIV-1 and
SIV (simian immunodeficiency virus) infections in vitro
with similar effectiveness [12] led us to analyze its efficacy
in the cat model. Initial in vivo studies using the predom-
inantly neurotropic FIV-PPR strain, showed that TL-3
treatment lowered plasma viral loads and resulted in a sig-
nificant protective effect against neurologic alterations in
the CNS in FIV infected cats [13]. In the present study, we
employed the highly pathogenic FIV-C isolate
(CABCpady00C), which causes a fulminant acute phase
disease in the periphery, with high death rates from acute
phase immunodeficiency disease [1].
Results
In Vivo Infection
Twenty-two female specific pathogen-free (SPF) cats were
randomly divided into five groups. Group 0 consisted of
two cats, which received TL-3 treatment without viral
infection and were considered controls. Group 1 (n = 5)
received 0.1 ml (105 RNA copies/ml) of FIV-C-infected
plasma I.V. with TL-3 drug treatment. Group 2 (n = 5)
received 0.1 ml FIV-C-infected plasma without TL-3 treat-
ment. Group 3 (n = 5) received 0.5 ml FIV-C-infected
plasma with TL-3 and Group 4 (n = 5) received 0.5 ml FIV-
C-infected plasma without TL-3 treatment. Blood (1 ml)
was drawn from all cats prior to the start of the experi-
ment, at weekly intervals for the first four weeks after
infection, and at bi-monthly intervals from week 4 until
the end of the study. Complete blood counts were
assessed as a function of infection and TL-3 treatment. In
addition, quantitative reverse transcription PCR (QRT-
PCR) analyses were performed to assess plasma viral load.
All animals were continuously observed for any changes
in general health. No significant differences were noted
between viral load or disease phenotype between the two
plasma dosages used in infection and subsequent discus-
sion will not distinguish between these two groups.
By week 6 post infection, seven animals (221, 222, 220,
234, 229, 219, 215) were showing clinical signs of debili-
tating acute phase disease. Four of the seven affected ani-
mals (215, 219, 220, 234) were from the untreated
groups, and three animals (222, 221, 229) were from the
TL-3 treated groups. Symptoms in all seven symptomatic
cats varied from conjunctivitis, anorexia, corneal ulcera-
tions, and gingivitis to increases in temperature, dermati-
tis and marked lethargy. Despite intensive antibiotic
treatment, the general state of health of 6 of the cats did
not improve (221, 220, 234, 229, 215, 219) and they
received mandated euthanasia between six to seven weeks
post-infection. Cat 222 (TL-3 treated) responded to anti-
biotic therapy and recovered from acute phase symptoms.
Control and infected cats gained weight at approximately
the same rate during the first 4 weeks post infection,
regardless of drug treatment status (Figure 1, data
expressed as a ratio to starting weight for each animal).
However, at 6 weeks post infection, three animals in the +
TL-3 cohort (Figure 1, upper panel) and three animals in
the -TL-3 cohort (lower panel) had lost weight. All three
of the animals in the -TL-3 cohort (bottom panel, shown
in red; 215, 220, and 234) required mandated euthanasia
prior to the next weighing at week 8. Cat 229 in the TL-3
treated cohort also required mandated euthanasia prior to
week eight. Cat 221 in the + TL-3 cohort was euthanized
on the same day as cat 229, but a final weight was not
recorded. Cat 219 of the -TL-3 cohort had a normal weight
at week 6, but required euthanasia at week 7, with an
approx. 10% weight loss relative to week 6 (data not
shown in figure). Thus, weight loss at week 6 occurred
with onset of severe acute phase disease. Cat 222 in the
TL-3 treated group (upper panel) responded to aggressive
rehydration and antibiotic therapy, gained weight, and
survived the acute phase. Cat 223 was never noticeably
symptomatic and it is unclear why this animal showed a
dip in weight at week 6 which it recovered by week 8.
Brainstem auditory evoked potential changes (BAEPs)
Previous studies using FIV-PPR showed that the isolate
induces marked and consistent delays in BAEPs of
infected cats and that TL-3 could reverse this effect [13].
We, therefore, analyzed the FIV-C infected animals for
similar BAEP delays with or without TL-3 treatment. Ani-
mals were analyzed at two-week intervals for the first eightRetrovirology 2004, 1:38 http://www.retrovirology.com/content/1/1/38
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Cat weight ratios as a function of FIV infection Figure 1
Cat weight ratios as a function of FIV infection. Cats infected with FIV-C in the presence and absence of TL-3 treatment 
were weighed regularly throughout the course of infection. Graphs depict weight of individual cats as a ratio to respective 
starting weight. Control cats were 213 and 214; green symbols. Weight ratios of cats that required euthanasia as a result of 
acute phase feline AIDS are shown in red.
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weeks of the experiment. Interestingly, no delays in BAEPs
were noted with FIV-C infection (data not shown) in spite
of high viral loads in the periphery (see below).
Viral load quantification
Plasma viral RNA loads were measured at regular intervals
throughout the experimental period to evaluate viral load
changes in cats treated with or without TL-3. Viral loads
ranged from undetectable to approximately 9 × 109 RNA
copies/ml plasma (Figure 2). Examination of plasma
viremia at 2 weeks (i.e. before an active immune
response) revealed little differences in viral loads between
cats in the TL-3 treated and untreated cohorts (Figure 2A).
In contrast, after 2 weeks of infection, the highest viremias
were found in cats not receiving TL-3 (compare + TL-3 to
-TL-3, Figure 2B). Moreover, of the 6 FIV symptomatic cats
that were euthanized due to the severity of clinical disease,
4 of these animals had received no TL-3 and 3 of these cats
Plasma viral loads of FIV infected cats as a function of TL-3 treatment and disease Figure 2
Plasma viral loads of FIV infected cats as a function of TL-3 treatment and disease. (A), normalized viral load (cop-
ies/ml × 106) at week 2; (B), and at peak viremia between weeks 0 – 6.5 in FIV infected cats treated with TL-3 (+TL-3, solid 
symbols) or untreated (-TL-3, open symbols). (C), peak viremia between weeks 0 to 6.5 post infection, in healthy (asympto-
matic) and symptomatic (euthanized) cats. The average value (largest horizontal bar, –) is plotted for each group. Equal vol-
umes of plasma were normalized using an external RNA spike and analyzed as detailed in Materials and Methods for the 
presence of FIV RNA by reverse-transcription real-time quantitative PCR. * indicate average values in (C) differ significantly (p 
≤ 0.05).
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presented with the highest viral load (compare open sym-
bols to filled symbols, Figure 2C).
Analysis of viremia patterns in individual cats during the
initial 8 week evaluation period yielded additional differ-
ences in the TL-3 treated vs. untreated groups. Although
infected cats showed an initial viral peak in the second
week post-infection, by week 4, viral loads decreased for
each cat and the average viral load for symptomatic and
asymptomatic cats was similar (Figures 3A and 3B). How-
ever, by week 6 the symptomatic group had an average
viral load of 2 × 108 copies/ml, 27 times more virus than
the average viral load of asymptomatic cats (compare Fig-
ures 3A and 3B). Half of the 6 symptomatic cats were
euthanized at week 6 due to severe illness. The remaining
three symptomatic cats (all from the untreated group) had
an average viral load of 3.2 × 108 copies/ml at 6.5 weeks
(Figure 3A) and required euthanasia by week 7. Within
the asymptomatic cohort, three (223, 224, 230) out of
eight TL-3 treated cats had reduced viral loads by week 4.
Their viral loads remained low during week 6 and at week
8, four of 8 surviving TL-3 treated animals had viral load
levels below detection limits. Of the six surviving animals
that had not received TL-3, only one cat (233) had a viral
load below detection limits at week 8 (Figure 3B).
Leukocyte Changes
Peripheral blood mononuclear cells (PBMC) were iso-
lated from whole EDTA-treated blood from each animal
and CD4+ and CD8+ T cell quantitations were performed
by flow cytometry and leukocyte counts. Absolute values
for CD4+ T cells showed a general decreasing trend in both
the TL-3-treated and untreated cohorts when all animals
were averaged in each group and CD8+ T cell counts and
neutrophils did not show significant variance from con-
trol values (data not shown). However, analysis of CD4+
and CD8+ T cells counts of symptomatic cats as compared
to treatment-matched asymptomatic animals showed
interesting differences (Figure 4A and 4B, resp.). The
CD4+ T cell population of the symptomatic cats decreased
progressively over the first 6-week period (Figure 4A).
CD4+ T cell counts of identically treated cats that showed
no signs of disease also decreased, but less precipitously
than those of animals eventually requiring euthanasia due
to severity of illness (p ≤ 0.05). Uninfected control ani-
mals maintained their T cell values during the same time
frame. The CD8+ population of T cells showed an even
more drastic decrease in the symptomatic animals com-
pared to the asymptomatic infected animals (Figure 4B).
Between weeks two and four, the CD8+ T cell population
in the symptomatic animals showed a small rebound
from week 2, then declined through week 6 post infection.
In contrast, CD8+  T cell counts in treatment-matched
asymptomatic animals increased significantly (p ≤ 0.05)
from week 2 onward, consistent with a strong CD8+ T cell
response in the protected cats.
Consistent with previous reports [14-16], we also
observed changes in the total neutrophil counts in the
symptomatic FIV-C infected cats. Within one week post-
infection, neutrophil numbers increased markedly in cats
220 (10, 962 cells/µl) and 234 (11, 926 cells/µl) as com-
pared to other cats with identical TL-3 treatment (average
= 6880 ± 2847 cells/µl). By week 4, neutrophil values fell
drastically in the same two cats (220: 558 cells/µl; 234:
416 cells/µl) as well as in cats 215 (420 cells/µl) and 221
(400 cells/µl). By week 6, four of the symptomatic cats
had neutrophil counts near zero. Only cat 220 slightly
recovered its neutrophil cell count (3675 cells/µl) prior to
mandated euthanasia.
Protease escape variants
Drug pressure induced viral resistance to protease inhibi-
tors represents one of the major hurdles of HIV HAART
treatment regimens [17,18]. HIV and FIV proteases share
only 23–28% overall identity at the protein level, yet the
enzymatic active site residues are virtually identical [19],
allowing a convenient side-by-side comparison. When
analyzing the surviving cohort of animals that had
received TL-3 treatment, we noted high viral loads in some
cats (Figure 3B; 222, 228, 231, 232) that remained ele-
vated (except 228) between weeks 6 and 8, relative to
other cats (Figure 3B; 223, 224, 230) that had significantly
lowered viral loads. We, therefore, analyzed plasma sam-
ples from symptomatic and asymptomatic TL-3 treated
animals to look for potential drug-resistance. The protease
gene was cloned from week 6 plasma of the two sympto-
matic TL-3 treated cats (221 and 229) and sequenced.
Twenty individual protease clone sequences revealed a
wild-type protease gene sequence (data not shown). We
then chose cats 231 and 228, two TL-3-treated asympto-
matic cats with relatively high viral loads in week 6 (Figure
3B), as well as cat 222, which overcame its disease syn-
drome with drug treatment. Cloning and sequencing of
the protease gene revealed a number of interesting muta-
tions (Table 1). The aspartic acid to glycine point muta-
tion at FIV protease residue 105 (D105G) occurred in cats
231 and 222. The equivalent site in HIV protease is resi-
due 88 (HIV88N), which is associated with development
of resistance to some HIV protease inhibitors [20]. Other
potentially relevant point mutants cloned from cat 231
were the H72R (HIV63L) and N55D (HIV46M) from
week 6 plasma and M107R (HIV90L) from week 8
plasma. The equivalent HIV residue escape mutants
exhibit various degrees of resistance against current pro-
tease inhibitors [20]. Additional multiple point muta-
tions, lying outside of the FIV protease active site or
having no apparent important HIV equivalents were also
observed (Table 1). The protease genes were cloned intoRetrovirology 2004, 1:38 http://www.retrovirology.com/content/1/1/38
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Individual plasma viral loads as a function of TL-3 treatment over an 8 week period Figure 3
Individual plasma viral loads as a function of TL-3 treatment over an 8 week period. Normalized viral loads in (A) 
symptomatic (euthanized) and (B) asymptomatic cats. Each value corresponds to the volume normalized viral load (copies /ml) 
between weeks 2–8. Control cats, 213 and 214 (not shown) had viral levels below detection. Cats are grouped for the pres-
ence (■  solid bars) or absence ( open bars) of TL-3 treatment, and then in numerical order from left to right. Specific bars 
are marked for the approximate week of euthanasia (†) and viral levels below detection are denoted as (*).Retrovirology 2004, 1:38 http://www.retrovirology.com/content/1/1/38
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expression vectors, expressed and purified for enzymatic
analysis. The findings revealed that most of the mutants
could not be distinguished from wild-type FIV-C protease
as to TL-3 susceptibility. However, mutant D105G exhib-
ited a Ki of 47.3 nM as compared to 9.9 nM for wild-type,
consistent with a 5-fold increase in resistance to TL-3.
Discussion
The protease inhibitor, TL-3, demonstrated broad efficacy
against FIV, SIV and HIV in tissue culture [12], as well as
against drug-resistant HIV isolates [21]. Furthermore, TL-
3 treatment had a very strong protective effect on early
neurologic alterations in the CNS of FIV-PPR infected cats
[13]. However, molecularly cloned FIV-PPR causes little
acute phase disease in the periphery. We, therefore,
sought to test TL-3 efficacy in vivo in the context of the
highly pathogenic, uncloned CABCpady00C species (FIV-
C) [1], which causes a severe acute phase immunodefi-
ciency syndrome, with high early mortality rates.
Although only partial protection was afforded by TL-3 in
our studies, the results are promising in that average peak
viral loads in some cats were lower in the presence of drug,
even in the face of a highly aggressive infection (Figure
2B).
Of 20 cats infected with uncloned FIV-C, seven animals
showed signs of immunodepletive disease early on (Fig-
ure 4) and developed full-fledged acute phase AIDS symp-
toms with anorexia, conjunctivitis, corneal ulcerations,
gingivitis and marked lethargy by week 6, mandating
euthanasia of six animals. The symptomatic cats had viral
RNA loads significantly higher (>108 RNA copies/ml, p ≤
0.05) than asymptomatic infected animals independent
of drug treatment. This finding suggests that the intense
viral infection severely compromised the immune system
leading to immunodeficiency and the development of
concomitant AIDS, as evidenced by the rapid loss of CD4+
T cells as well as neutrophils in the affected cats during the
first few weeks (Figure 4). Cats receiving TL-3 treatment
had lower peak viral loads compared to cats not receiving
TL-3 at weeks 4 and 8, indicating that the protease inhib-
itor reduced systemic expansion of viral infection. Previ-
ous studies have correlated disease progression with high
initial peak viral loads [22]. Of the five out of eight cats
treated with TL-3 and having higher viral loads at weeks 4
and 8 compared to non-TL-3-treated cats, three (222, 228,
231) were evaluated for FIV resistance to TL-3. None of
the protease genes recovered from cat 228, whose viral
levels fell below detection at week 8, showed evidence of
TL-3 resistance. However, cats 222 and 231 were found to
harbor virus in the plasma that encoded TL-3 resistant
protease. In particular, a D105G mutant demonstrated a
5-fold resistance to TL-3 relative to wild type protease,
which may indicate the onset of drug resistance develop-
ment and explain the higher viral levels in some of the TL-
3 treated cats. Preparation of isogenic virus containing the
D105G point mutation will allow the direct determina-
tion of potential drug resistance.
Peripheral CD4+ and CD8+ lymphocyte levels as a function of  clinical outcome over 8 weeks Figure 4
Peripheral CD4+ and CD8+ lymphocyte levels as a 
function of clinical outcome over 8 weeks. A) Total 
CD4+ cells per ml average and standard error of the mean; 
B) Total CD8+ cells per ml average and standard error of the 
mean. Symbols: ● : uninfected cats (213 and 214);  Sympto-
matic cats (215, 219–221, 229 and 234);  asymptomatic cats 
(216–218, 222–228, 230–233). * indicate values between 
symptomatic and asymptomatic cats differ significantly (p ≤ 
0.05).
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Interestingly, TL-3 treated cats with highest viral loads
(221 and 229) developed severe disease syndromes,
which suggests that TL-3 efficacy was limited to a specific
viral threshold in this study. Once the threshold has been
crossed, TL-3 may not be able to overcome the full-blown,
acute, viral infection, resulting in rapid onset of immune
suppression.
We were unable to show any correlation between
humoral antibody responses and clinical outcome (data
not shown). However, a consistent observation was a
marked and progressive increase of CD8+  T cells in
animals surviving the acute phase infection and a lack of
such responses in animals that required euthanasia within
the first 8 weeks following infection. Although not for-
mally tested, the findings imply a strong cell-mediated
response in the surviving animals contributed to control-
ling the viral infection.
The above analyses underscore the natural variation in the
response to FIV challenge in outbred cats, similar to the
observed variation in responses to HIV infection in
humans. However, more consistent responses, both in
peak viral loads (Figure 2) and in lymphocyte counts (Fig-
ure 4) were seen when animals were analyzed as a func-
tion of disease severity. Thus, the question arises as to
whether there is a genotypic link to susceptibility. Upon
close scrutiny of the parental heritage pattern, we
observed that one male in particular (96AGQ1) had sired
eight of the experimental animals with three different
females (Table 2). Two of his offspring (213, 214) had
been randomly placed into the uninfected control group,
while of the remaining six offspring, four (215, 219, 220,
221) succumbed to FIV induced disease. One of the sur-
viving siblings (222) was in the TL-3 treatment group and
exhibited conjunctivitis and possible corneal ulceration
and was mildly to moderately lethargic. Cat 222 received
Baytril treatment and fluid replacement therapy and even-
tually recovered from her symptoms. The last sibling
(216) never showed any detectable signs of disease
throughout the experiment. Although complicating the
analyses and statistical treatments, the variable responses
with FIV infection of cats parallels those observed with
HIV infection in humans and thus affords a relevant
model for study of infection and treatment modalities. As
with humans, cats are outbred, which complicates
defining susceptibility markers. However, identifying the
genetic basis for susceptibility in the cat may yield impor-
tant clues to similar phenomena in humans.
Viral protease inhibitors are of paramount importance for
HIV treatment and successful tempering of viral infection.
However, drug resistant escape variants are an important
consideration in treatment protocols [17,18]. Although
we previously failed to isolate TL-3-resistant FIV in vitro,
the findings here suggest that in vivo, drug resistance to the
compound may develop. The results were not unexpected
in that we had been able to develop TL-3 resistant HIV var-
iants [21] and it seemed unlikely that FIV would prove an
exception. The finding of drug resistant mutants, in fact,
strongly indicates that the feline/FIV model is valuable in
the assessment of the ability of other protease drugs and
drug cocktails to suppress virus infection and limit drug
resistance development.
Conclusions
The findings indicate that the protease inhibitor TL-3,
when given orally as a monotherapy, did not prevent
viremia in cats infected with a high dose challenge with
FIV-C and substantial virus loads were evident in circula-
tion throughout the acute phase (between 2–6 weeks post
infection) in all infected animals, regardless of drug regi-
Table 1: FIV Protease Escape Mutants (HIV equivalent residue)
PR mutations Ki vs TL-3 (nM)
Wildtype PR ---- 9.9
Cat 231 D105G (HIV88N) 47.3
D94G (*) N.D.
H72R (HIV63L) 10.9
N55D (HIV46M) 9.1
G52R (HIV43K) N.D.
1M107R (HIV90L) inactive
1N51Y (HIV42W) N.D.
Cat 228 C69R (HIV60D) N.D.
Cat 222 D105G (HIV88N) 47.3
1 isolated from 8th week plasma
* no HIV equivalent site
Bold type, FIV-C point mutant of interest
N.D. not determinedRetrovirology 2004, 1:38 http://www.retrovirology.com/content/1/1/38
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men. Average peak viral loads in the acute phase were
lower in TL-3 treated animals, but variability was such that
the numbers did not reach statistical significance. How-
ever, of six animals that required euthanasia, four were
from the untreated cohort and two were from the TL-3
treated group. Additionally, at eight weeks post infection,
half the surviving TL-3 treated animals had viral loads
below the detection limits, whereas only one of six
untreated animals had markedly reduced viral loads.
Thus, therapeutic benefit was noted with TL-3 treatment,
even in the face of an aggressive FIV infection.
The findings also show clear differences in the lymphocyte
responses of animals that succumb to acute phase illness
versus those that survive to the asymptomatic phase. The
most pronounced difference was in the lack of an increase
in CD8+ cell numbers starting around three weeks post
infection in animals that eventually required humane
euthanasia versus a pronounced and significant increase
in CD8+ T cell numbers in animals that survived the acute
phase.
Certain animals that received TL-3 had higher than aver-
age viral loads after the acute phase. Analyses of the pro-
tease genes of FIV quasi-species prevalent in these animals
revealed sequence variations relative to protease of wild
type FIV-C. One particular protease, cloned and expressed
from two TL-3-treated animals, contained the mutation
D105G, which imparted 5-fold resistance against TL-3 rel-
ative to wild type protease. This may represent the initial
stages of drug resistance development and preparation of
this mutation in the context of isogenic virus will address
this issue. The findings suggest that the cat model will
serve as a valuable animal model for study of resistance
development against lentivirus infections.
Materials and methods
Animals
22 female purpose-bred 8–9 week old kittens purchased
from Liberty Laboratories were inspected upon arrival for
signs of illness, examined by a veterinarian and weighed.
Animals were maintained in a 2-week quarantine and
observed for any signs of illness prior to the beginning of
the study. IACUC number ARC 61 JAN 3.
Viral Infection
Plasma samples (105 RNA copies/ml) from a cat, that had
died from an acute infection with CABCpady00C (FIV-C),
were kindly provided by Dr. E. Hoover, of Colorado State
University. Cats were injected I.V. with either 0.1 ml (105
RNA copies/ml) or 0.5 ml of plasma.
Drug Dosing
All procedures for care of cats during dosing as well as dos-
ing procedures were mandated by TSRI's IACUC. Oral TL-
3 (L-Iditol,1,2,5,6-tetradeoxy-1,6-diphenyl-2,5-bis [N-
[(phenylmethoxy)carbonyl]-L-alanyl-L-valyl]amino])
[12] treatment was initiated in 12 cats, three days prior to
infection of ten of the twelve animals with FIV-C. All TL-3
treated animals received 20 mg TL-3 by capsules at eight
hour intervals, for approx. the first 7.5 weeks of the
experiment. Dosage was then doubled to 40 mg TL-3 per
dose at eight hour intervals for an additional week for the
two control animals and the eight surviving animals in the
TL-3 treated, infected cohort. No adverse effects were
noted in the uninfected, TL-3 treated controls.
Table 2: Feline Lineages
Dam Sire Siblings
99AIE3 96AGQ1‡ 213* 214* 215† 216
00AIB4 96AAK4 217 218
98AXS5 96AGQ1‡ 219† 220†
00ANU5 96AGQ1‡ 221† 222
00AJT2 96ACJ2 224
01TBK5 99IAS1 225 226 227
01QAL4 00XAZ4 228
01QEJ3 98ATY2 229†
01QBJ3 00IRX4 230
95PAA3 98IUU1 231
01IQP4 98IUG3 232 233
00XBA1 00XAG1 234†
* control animals
† sacrificed animals
Bold type, offspring from same sire (‡)
 survivor offspring of sireRetrovirology 2004, 1:38 http://www.retrovirology.com/content/1/1/38
Page 10 of 12
(page number not for citation purposes)
Evoked Potentials
Uninfected and FIV-infected animals were intermittently
scheduled for analyses of evoked potentials in conjunc-
tion with the blood sampling, including testing for both
auditory and visual evoked potentials as previously
described [23]. Once recordings were complete, a blood
sample was collected and animals returned to the
vivarium.
Clinical Evaluation
Animals were examined daily and in case of health con-
cerns further therapy/diagnostics were initiated. Animals
with abnormal weight, or on antibiotics were placed on
supplemental feeding with moist food and Nutrical.
Dehydrated animals received subcutaneous fluid therapy.
More affected animals received supportive care and medi-
cations, consisting of BID administration of antibiotics
(Baytril), BID subcutaneous fluid therapy, BID tempera-
ture evaluation, BID application of antibiotic ophthalmic
ointment supportive care. Any animals that required
extensive supportive care (TID fluid therapy, TID force
feeding) were euthanized. Euthanasia of research animals
was conducted with strict adherence to NIH Office of Lab-
oratory Animal Welfare protocols.
Blood Collection and Peripheral Blood Separation
Blood samples (1 ml/animal) were collected weekly dur-
ing the first month of the study and then every two weeks
thereafter, as described [13]. Samples were placed in
EDTA blood tubes (1 cc/tube) for further use.
Plasma was separated from blood by centrifugation at
3000 rpm for 5 minutes at room temperature. Blood cells
were resuspended in 3 ml PBS and PBMC were separated
from buffy coats by density gradient centrifugation using
Ficoll-Hypaque Plus (Amersham Biosciences, Sweden).
PBMC were washed once in PBS and twice in PBS/2% FBS
for flow cytometry analyses.
Statistical Analysis
Statistical p values for the FIV-C viral load were deter-
mined by the Student's two-tailed t-test (paired, two-
tailed distribution between the treated and non-treated
group and the symptomatic vs asymptomatic group). Sta-
tistical p values for the weekly total CD4 and CD8 cell
counts were also determined by the Student's two-tailed t-
test (paired, two-tailed distribution compared to base line
levels at week 0).
Flow Cytometry Analysis
Two-color flow cytometry analysis was performed on cells
stained with mouse α-feline CD4 FITC and mouse α-
feline CD8 PE (Southern Biotech, Birmingham, AL). Anti-
mouse IgG1κ FITC and PE (BD PharMingen, San Diego,
CA) were used as isotype controls. Cells were fixed with
2% PFA prior to analysis performed on a FACScan flow
cytometer (Beckton Dickenson Immunocytometry Sys-
tems) using the Cell Quest Software program.
RNA Isolation and Reverse Transcription
Plasma for weeks 0, 2, 4, 6 (terminal points for cats 215,
221, and 229), 6.5 (terminal points for cats 219, 220, and
234), and 8, were isolated from whole blood by centrifu-
gation and stored at -20°C. Viral RNA was extracted using
the QiaAmp Viral RNA Isolation Kit (Qiagen, Valencia,
CA) according to manufacturer's instructions with slight
modifications: Plasma samples (280 µl) were lysed in
buffer AVL (1,120 µl) (Qiagen) for 10 minutes at room
temperature in the presence of carrier RNA (10 µg/ml)
and an external Kanamycin (KAN) RNA spike. Equal
amounts of the external RNA spike (109 copies RNA /280
µl plasma), corresponding to the 1.2 kb KAN gene
(Promega, Madison, WI), was used to normalize plasma
volumes between samples and to correct for sample loss
from viral RNA extraction and cDNA synthesis. An on-col-
umn DNase/ RNase free (Qiagen) incubation step for 10
minutes at room temperature was added to remove resid-
ual cellular DNA. Complimentary DNA (cDNA) was gen-
erated in a 20 µl total reaction using 13 µl of sample RNA,
0.5 µl (2 µM stock) each of KAN and FIV specific reverse
primers (sequences below) and StrataScript reverse tran-
scriptase, following the manufacturer's protocol (Strata-
gene, La Jolla, CA). After incubation, each cDNA sample
was diluted in water to 30 µl and stored at -80°C for use
in real-time PCR.
Real-Time Quantitative PCR
25 µl real-time PCR reactions were set up containing 2X
Platinum Quantitative PCR SuperMix-UDG (12.5 µl)
(Invitrogen, Carlsbad, CA), forward, reverse primers and
probe mix (7.5 µl), and cDNA target (5 µl). The mixture
was incubated at 50°C for 2 minutes, 95°C for 10 min-
utes, then cycled at 95°C for 15 seconds and 60°C for 60
seconds 55 times, using the ABI Prism 7700 Sequence
Detection System (Applied Biosystems, Foster City, CA).
Data were analyzed using the ABI 7700 Sequence Detec-
tion Software. Forward and reverse primers (10 nM, 100
nM, final concentration respectively) used in real-time
PCR were made at IDT, (Coralville, IA), while the fluores-
cein-dabsyl Amplifluor UniPrimer (100 nM final concen-
tration) was purchased from Serologicals (Norcross, GA).
The primer sequences used for real-time PCR are as
follows:
FIV reverse-transcriptase forward: 5'-ACTGAACCTGAC-
CGTACAGATAAATTACAGGAA GAACCCCCATA-3'
FIV reverse-transcriptase reverse: 5'-TGTTAATGGATG-
TAATTCA TAACCCATC-3'Retrovirology 2004, 1:38 http://www.retrovirology.com/content/1/1/38
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KAN forward: 5'-ACTGAACCTGACCGTACACGCTCAG-
GCGCAATCAC-3'
KAN reverse: 5'-CCAGCCATTACGCTCGTCAT-3'
Standard Curves and Background Detection
To determine the relative copy numbers of KAN and FIV
from plasma samples, a linear standard curve was gener-
ated by plotting 10-fold dilutions (5 × 108 to 5 × 102 cop-
ies per well) of dsDNA plasmids of known copy number
(log scale), against the cycle threshold (Ct) determined for
that value. The pET28 vector (Novagen) was used as the
target plasmid for the KAN gene, while a plasmid contain-
ing the molecular clone of FIV-C was used for the FIV
reverse-transcriptase gene. Calculated values for each
plasma sample represent relative  copy numbers for the
purposes of evaluation between individual samples.
Cloning, Purification and Analysis of Protease
Complementary DNA (cDNA) was synthesized from iso-
lated plasma viral RNA of infected cats. The cDNA pool
was used as a template for PCR reactions using 5' primer
MFIVCPL5' (5'-GATTTATAAATCATATG GCAT-
ATAATAAAGTGGGTACCACTACAACATTAG-3'), which
adds an NdeI restriction site, methionine, and alkaline to
the N-terminal of the protease and 3' primer MFIVCPL33'
(5'-CTGAGATCTGAGCAAGCTTTTACATTACTAATCT
AATATTAAATTTAACCATG TTATC-3'), which adds a stop
codon and a Hind III restriction site to the C-terminus of
the protease. The amplified PCR product was gel purified
and cloned into pCR-TOPOII vector (Invitrogen,
Carlsbad, CA) for sequencing. Selected DNA of mutants,
N55D, H72R, D105G, and M107R were digested with
Nde I/Hind III and ligated into pET21a expression vector
(Novagen). The mutant FIV-C proteases were expressed in
Rosetta pLysS cells (Novagen) and purified as previously
described [24].
Enzyme kinetics of FIV-C protease were assayed on the
flourogenic substrate Arg-Ala-Leu-Thr-Lys(Abz)-Val-Gln/
Phe(NO2)-Val-Gln-Ser-Lys-Gly-Arg-NH2. The concentra-
tion was determined by active-site titration with inhibitor
TL-3. Inhibitor constant (Ki) of TL-3 against mutant FIV-C
protease was analyzed as described [25].
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